Regeneron Quarterly Profit Plunges 46 Percent as Eye Drug Sales Drop, COVID Drug Sales Dry Up

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, on Sept. 17, 2020. Brendan McDermid/Reuters

Regeneron Pharmaceutical’s fourth-quarter profit was negatively impacted after sales of its COVID antibody cocktail dried up and lackluster sales of its blockbuster eye drug, Eylea, but sales of its eczema drug Dupixent helped recover some losses.

The pharmaceutical company’s quarterly report, released on Feb. 3, saw earnings fall by 46 percent due to reports of diminished sales of Eylea and negative demand for its COVID antibody drug REGEN-COV.